Head, Oncology Clinical Development - ADCs
Leads end-to-end clinical development of an antibody-drug conjugate (ADC) oncology asset across multiple tumor types, from first-in-human through registrational trials and market launch. Drives integrated clinical strategy, translational research, regulatory submissions, and cross-functional collaboration across global teams. Engages with governance bodies, scientific advisory boards, and external experts to shape development and competitive positioning.